Purple Biotech Ltd.
- PPBT
- NASDAQ
- Biotechnology
- Oncology Biotech (Clinical-Stage)
- Cancer Therapeutics (Immunotherapy)
$1.10
Today −3.51%Quote Oct 19, 2026, 07:34 PM UTC
−26.21%over the last month
Max drawdown −26.9%From 1-month high −26.9%3 months −21.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Purple Biotech
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
10
Market value
$2.04B
Quote Oct 19
Floor
$1.02
7.0% below price
Resistance
$1.18
7.0% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PPBTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free